Evolution of remission as the new standard
in the treatment of depression
by
Nierenberg AA, Wright EC
Depression Clinical and Research Program,
Massachusetts General Hospital,
Department of Psychiatry,
Harvard Medical School,
Boston 02114, USA
J Clin Psychiatry 1999; 60 Suppl 22:7-11

ABSTRACT

Epidemiologic and clinical data support the goal of treating depressed patients to wellness or full remission. Many patients improve but fail to achieve full remission with antidepressant treatment and continue to have residual symptoms, which cause distress and dysfunction. These residual symptoms may meet criteria for subsyndromal and minor depression. Patients who have these milder syndromes after treatment have a greater risk of relapse and recurrence than do those who remain symptom-free. Clinical trials of antidepressants have shown lower rates of remission than of responses that fall short of remission, although some dual-acting antidepressants (e.g., serotonin-norepinephrine reuptake inhibitors) may have higher remission rates than other agents. Treatment with such robust dual-acting antidepressants may result in higher rates of remission and fewer residual symptoms than treatment with selective serotonin reuptake inhibitors.

SSRIs
Anxiety
Serotonin
Dopamine
Noradrenaline
Venlafaxine profile
Venlafaxine compared
Venlafaxine v fluoxetine
Venlafaxine pharmacology
Venlafaxine plus bupropion
Venlafaxine and depression
Venlafaxine for treatment-resistant depression

Refs
HOME
HedWeb
Cocaine.org
Future Opioids
BLTC Research
Superhappiness?
Paradise-Engineering
The Abolitionist Project
The Hedonistic Imperative
MDMA: Utopian Pharmacology

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family